Compare NRG Energy Inc (NRG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Recursion Pharmaceuticals Inc — how do they compare? NRG Energy Inc trades at $108.49 (market cap $22.35B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: NRG Energy Inc is far larger — about 10.4× Recursion Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 62 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NRG | RXRX | |
|---|---|---|
Market Cap | $22.35B | $2.14B |
Volume | 5,011,942 | 30,789,535 |
Sector | Utilities | Health |
52-Week High | $184.03 | $6.79 |
52-Week Low | $95.23 | $2.84 |
Typical Hold Time | 62 Days | 22 Days |
Enterprise Value | $46.30B | $1.66B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $108.61, up 4.84% with bullish technical signals and strong analyst support. The stock shows robust fundamentals with $30.71B revenue, 2.56% net margin, and attractive valuation at P/E 28.28 and P/S 0.66. Recent developments include a transformative 1.2 GW Texas data center power project and LS Power acquisition driving growth. Cash flow trends improved significantly from 2023's negative $1.5B to 2025's positive $3.83B, though 2026 projects a temporary dip.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus target representing 87% upside. Key opportunities include data center expansion and customer-backed power projects, while risks involve elevated debt levels (56.42% debt-to-asset ratio) and recent earnings misses. The stock presents growth potential but requires monitoring of execution on major capital projects.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
